Orazio Caffo, MD, Santa Chiara Hospital, Pisa, Italy, discusses analysis into post-progression therapies for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel. Docetaxel-treated patients are thought to have lower disease-free survival (DFS) rates, but this analysis suggests the patient’s treatment response is more relevant. Dr Caffo states that patients with shorter control from docetaxel are prompted to receive cabazitaxel whilst patients with more prolonged disease control are prompted to receive enzalutamide or abiraterone. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.